Category: hypoactive sexual desire dysfunction HSDD
IMS: Sexual wellbeing after menopause
Patient Support Material: Free yourself and embrace positive sexual wellbeing Sexual health is a state of physical, emotional, mental and social wellbeing related to… Continue Reading →
Share your opinions as a woman with POI/ Premature menopause.
International POI guideline update survey What matters for you? A 10 minute scoping survey for women or for health professionals: An international collaboration between the European… Continue Reading →
Share your opinions as a woman with POI/ Premature menopause.
International POI guideline update survey What matters for you? A 10 minute scoping survey for women or for health professionals: An international collaboration between the European… Continue Reading →
IMS: Sexual wellbeing after menopause
Free yourself and embrace positive sexual wellbeing Sexual health is a state of physical, emotional, mental and social wellbeing related to sexuality. After menopause… Continue Reading →
Perimenopause Online Event : May 3-4 2022
Get Your Tickets Here. Finally, Help Has Arrived. Expert advice, from the people who really know perimenopause. Streaming online and includes on-demand access: May 3-4 2022… Continue Reading →
AndroFeme 1 included on ARTG for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals’ female-specific hormone cream, AndroFeme® 1, has been registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
AndroFeme 1 licensed for hypoactive sexual desire dysfunction in postmenopausal women
Lawley Pharmaceuticals has obtained approval for registration of AndroFeme® 1 in the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1
Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.
TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019 — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →